Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Genentech

< Previous 1 2 3 4 5 6 Next >

Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024

November 05, 2024

From Genentech

Via Business Wire

New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer

October 30, 2024

From Genentech

Via Business Wire

Genentech’s Vabysmo Improved Vision in Underrepresented Populations With Diabetic Macular Edema (DME) in a First-Of-Its-Kind Study

October 18, 2024

From Genentech

Via Business Wire

Majority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate

October 14, 2024

From Genentech

Via Business Wire

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

October 10, 2024

From Genentech

Via Business Wire

Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis

September 26, 2024

From Genentech

Via Business Wire

Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses

September 19, 2024

From Genentech

Via Business Wire

FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

September 13, 2024

From Genentech

Via Business Wire

FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

September 12, 2024

From Genentech

Via Business Wire

New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

July 18, 2024

From Genentech

Via Business Wire

Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study

July 17, 2024

From Genentech

Via Business Wire

Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity

July 17, 2024

From Genentech

Via Business Wire

Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)

July 08, 2024

From Genentech

Via Business Wire

FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss

July 05, 2024

From Genentech

Via Business Wire

Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer

July 04, 2024

From Genentech

Via Business Wire

Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

June 15, 2024

From Genentech

Via Business Wire

Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk

June 07, 2024

From Genentech

Via Business Wire

FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

May 29, 2024

From Genentech

Via Business Wire

FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

May 21, 2024

From Genentech

Via Business Wire

Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity

May 16, 2024

From Genentech

Via Business Wire

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

April 18, 2024

From Genentech

Via Business Wire

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

April 17, 2024

From Genentech

Via Business Wire

Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study

April 15, 2024

From Genentech

Via Business Wire

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies

February 25, 2024

From Genentech

Via Business Wire

FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies

February 16, 2024

From Genentech

Via Business Wire

New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

February 01, 2024

From Genentech

Via Business Wire

FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results

December 19, 2023

From Genentech

Via Business Wire

New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma

December 10, 2023

From Genentech

Via Business Wire

New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A

December 09, 2023

From Genentech

Via Business Wire

Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

December 08, 2023

From Genentech

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.